Cognitive deficits in Parkinson's disease: A cognitive neuroscience perspective

Movement Disorders

Volumn 29, Issue 5, 2014, Pages 597-607

  Robbins, Trevor W ^a   Cools, Roshan ^b  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b RADBOUD UNIVERSITY NIJMEGEN   (Netherlands)

Author keywords

Attention; Cognition; Dopamine; Executive function; Memory; Prefrontal cortex; Striatum

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; CATECHOL METHYLTRANSFERASE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA;

AKINESIA; ALZHEIMER DISEASE; ANTERIOR CINGULATE; BRADYKINESIA; BRADYPHRENIA; CAUDATE NUCLEUS; COGNITION; COGNITIVE DEFECT; CORPUS STRIATUM; DIFFUSE LEWY BODY DISEASE; DOPAMINERGIC NERVE CELL; EPISODIC MEMORY; EXECUTIVE FUNCTION; FOREBRAIN; FUNCTIONAL NEUROIMAGING; GENETIC SCREENING; GLOBUS PALLIDUS; HABIT; HUMAN; HUNTINGTON CHOREA; HYPOTHESIS; INFERIOR TEMPORAL CORTEX; LEARNING; LEARNING DISORDER; LEARNING THEORY; LEWY BODY; LOCUS CERULEUS; MILD COGNITIVE IMPAIRMENT; NEUROPATHOLOGY; NEUROPSYCHOLOGICAL TEST; NEUROSCIENCE; NONHUMAN; NUCLEUS ACCUMBENS; ORBITAL CORTEX; PARKINSON DISEASE; POSTERIOR PARIETAL CORTEX; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROCEDURAL MEMORY; PSYCHOPHARMACOLOGY; PUTAMEN; RECALL; RECOGNITION; REINFORCEMENT; REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SPATIAL MEMORY; SUBSTANTIA INNOMINATA; SUBSTANTIA NIGRA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMUS; SUPPLEMENTARY MOTOR AREA; THALAMUS VENTRAL NUCLEUS; VENTRAL TEGMENTUM; WORKING MEMORY; ANIMAL; COGNITION DISORDERS; COMPLICATION; DEMENTIA; MEMORY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; COGNITION; COGNITION DISORDERS; DEMENTIA; HUMANS; MEMORY; PARKINSON DISEASE;

EID: 84898835450     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25853     Document Type: Review

References (111)

1. Parkinson J. An essay on the shaking palsy. 1817. J Neuropsychiatry Clin Neurosci 2002;14:223-236.
2. Charcot J-M. On paralysis agitans (Lecture V). In: Lectures on the Disease of the Nervous System. London, UK: New Sydenham Society; 1877:129-156.
3. Squire LR. Memory systems of the brain: a brief history and current perspective. Neurobiol Learn Mem 2004;82:171-177.
4. Alexander GE, DeLong MR., Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. Ann Rev Neurosci. 1986:9:357-381.
5. Lees AJ, Smith E. Cognitive deficits in the early stages of Parkinson's disease. Brain 1983;106:257-270.
6. Boller F, Passafiume D, Keefe NC, et al. Visuospatial impairments in Parkinson's disease: role of perceptual and motor factors. Arch Neurol 1984;41:485-490.
7. Taylor AE, Saint-Cyr JA, Lang AE. Frontal lobe dysfunction in Parkinson's disease. Brain 1986;109:845-883.
8. Taylor AE, Saint-Cyr JA, Lang AE. Parkinson's disease: cognitive changes in relation to treatment response. Brain 1987;110:35-51.
9. Brown RG, Marsden CD. Internal versus external cues and the control of attention in Parkinson's disease. Brain 1988;111:323-345.
10. Brown RG, Marsden CD. "Subcortical dementia": the neuropsychological evidence. Neuroscience 1988;25:363-387.
11. Sagar HJ, Cohen NJ, Sullivan EV. Remote memory function in Alzheimer's disease and Parkinson's disease. Brain 1988;111:185-206.
12. Sagar H, Sullivan EV Gabrieli J, et al. Temporal ordering and short-term memory deficits in Parkinson's disease. Brain 1988;111:525-539.
13. Sahakian BJ, Morris RG, Evenden JL, et al. A comparative study of visuospatial memory and learning in Alzheimer-type dementia and Parkinson's disease. Brain 1988;111:695-718.
14. Gotham AM, Brown RG, Marsden CD. "Frontal" cognitive function in patients with Parkinson's disease 'on' and 'off levodopa. Brain 1988;111:299-321.
15. Saint-Cyr JA, Taylor AE, Lang AE. Procedural learning and neostriatal dysfunction in man. Brain 1988;111:941-959.
16. Canavan AGM, Passingham RE, Marsden CD, et al. The performance on learning tasks of patients in the early stages of Parkinson's disease. Neuropsychologia 1989;27:141-156.
17. Downes JJ, Roberts AC, Sahakian BJ, et al. Impaired extra-dimensional shift performance in medicated and unmedicated Parkinson's disease: evidence for a specific attentional dysfunction. Neuropsychologia 1989;27:1329-1343.
18. Ogden JA, Growdon JH, Corkin S. Deficits on visuospatial tests involving forward planning in high-functioning parkinsonians. Neuropsychiatry Neuropsychol Behav Neurol 1990;3:125-139.
19. Cooper JA, Sagar H, Jordan N, et al. Cognitive impairment in early, untreated Parkinson's disease and its relationship to motor disability. Brain 1991;114:2095-2122.
20. Lange KW, Robbins TW, Marsden CD, et al. L-dopa withdrawal in Parkinson's disease selectively impairs cognitive performance in tests sensitive to frontal lobe dysfunction. Psychopharmacology 1992;107:394-404.
21. Owen AM, James M, Leigh PN, et al. Fronto-striatal cognitive deficits at different stages of Parkinson's disease. Brain 1992;115:1727-1751.
22. Owen AM, Beksinska M, James M, et al. Visuospatial memory deficits at different stages of Parkinson's disease. Neuropsychologia 1993;31:627-644.
23. Mahieux F, Fenelon G, Flahault A, et al. Neuropsychological prediction of dementia in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:178-183.
24. Levy G, Jacobs DM, Tang MX, et al. Memory and executive function impairment predict dementia in Parkinson's disease. Mov Disord 2002;17:1221-1226.
25. Janvin C, Aarsland D, Larsen JP, et al. Neuropsychological profile of patients with Parkinson's disease without dementia. Dement Geriatr Cogn Disord 2003;15:126-131.
26. Gauggel S, Rieger M, Feghoff TA. Inhibition of ongoing responses in patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 2004;75:539-544.
27. Rogers D, Lees AJ, Smith E, et al. Bradyphrenia in Parkinson's disease and psychomotor retardation in depressive illness: an experimental study. Brain 1987;110:761-776.
28. Owen AM, Roberts AC, Hodges JR, et al. Contrasting mechanisms of impaired attentional set-shifting in patients with frontal lobe damage or Parkinson's disease. Brain 1993:116:1159-1175.
29. Brozoski TJ, Brown RM, Rosvold HE, et al. Cognitive deficit caused by regional depletion of dopamine in prefrontal cortex of rhesus monkey. Science 1979;205:929-931.
30. Lewis SJG, Slabosz A, Robbins TW, et al. Dopaminergic basis for deficits in working memory but not attentional set-shifting in Parkinson's disease. Neuropsychologia 2005;43:823-832.
31. Cools R, Stefanova E, Barker RA, et al. Dopaminergic modulation of high level cognition in Parkinson's disease: the role of prefrontal cortex by PET. Brain 2002;125:584-594.
32. Lewis SJG, Dove A, Robbins TW, et al. Striatal contributions to working memory: a functional magnetic resonance imaging study in humans. Eur J Neurosci 2004;19:755-760.
33. Slabosz A, Lewis SJ, Smigasiewicz K, et al. The role of learned irrelevance in attentional set-shifting impairments in Parkinson's disease. Neuropsychology 2006;20:578-588.
34. Chan-Palay V, Asan E. Alterations in catecholamine neurons of the locus coeruleus in senile dementia of the Alzheimer type and in Parkinson's disease with and without dementia and depression. J Comp Neurol 1989:287:373-392.
35. Dubois B, Ruberg M, Javoy-Agid F, et al. A subcortico-cortical cholinergic system is affected in Parkinson's disease. Brain Res 1983;288:213-218.
36. Jellinger KA. Pathology of Parkinson's disease. Changes other than the nigrostriatal pathway. Mol Chem Neuropathol 1991;14:153-197.
37. Scatton B, Javoy-Agid F, Rouquier L, et al. Reduction of cortical dopamine, noradrenaline, serotonin and their metabolites in Parkinson's disease. Brain Res 1983;275:321-328.
38. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-2518.
39. Bohnen N I, Kaufer DI, Ivanco LS, et al. Cortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic study. Arch Neurol 2003;60:1745-1748.
40. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003;24:197-211.
41. Swainson R, Rogers RD, Sahakian BJ, et al. Probabilistic learning and reversal deficits in patients with Parkinson's disease or frontal or temporal lobe lesions: possible adverse effects of dopaminergic medication. Neuropsychologia 2000;38:596-612.
42. Kish SJ, Shannak K, Hornykiewicz O. Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N Engl J Med 1988;318:876-880.
43. Cools R, Barker RA, Sahakian BJ, et al. Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 2001;11:1136-1143.
44. Cools R, Barker RA, Sahakian BJ, et al. L-dopa medication remediates cognitive inflexibility, but increases impulsivity in patients with Parkinson's disease. Neuropsychologia 2003;41:1431-1441.
45. Rowe JB, Hughes L, Ghosh BC, et al. Parkinson's disease and dopaminergic therapy-differential effects on movement, reward and cognition. Brain 2008;131:2094-2105.
46. Aarts E, Helmich RC, Janssen MJR, et al. Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. Neuroimage 2012;59:3339-3346.
47. Evans AH, Lawrence AD, Potts J, Appel S, Lees AJ. Factors influencing susceptibility to compulsive dopaminergic drug use in Parkinson disease. Neurology 2005;65:1570-1574.
48. Cools R, Lewis SJ, Clark L, et al. L-DOPA disrupts activity in the nucleus accumbens during reversal learning in Parkinson's disease. Neuropsychopharmacology 2007;32:180-189.
49. Schultz W. Getting formal with dopamine and reward. Neuron 2002;36:241-263.
50. Corlett PR, Murray GK, Honey GD, et al. Disrupted prediction-error in psychosis: evidence for an associative account of delusions. Brain 2007;130:2387-2400.
51. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am J Psychiatry 2003;160:13-23.
52. Thanvi BR, Munshi SK, Vijaykumar N, et al. Neuropsychiatric non-motor aspects of Parkinson's disease. Postgrad Med J 2003;79:561-565.
53. Foltynie T, Goldberg TE, Lewis SG, et al. Planning ability in Parkinson's disease is influenced by the COMT val158met polymorphism. Mov Disord 2004;19:885-891.
54. Mattay VS, Callicott JH, Fera F, et al. Catechol-O-methyltransferase val (158)-met genotype and individual variation in the response to amphetamine. Proc Natl Acad Sci USA 2003;100:6186-6191.
55. Kaasinen V, Nurmi E, Bruck A, et al. Increased frontal [(18)F]fluorodopa uptake in early Parkinson's disease: sex differences in the prefrontal cortex. Brain 2001;124:1125-1130.
56. Rakshi J, Uema T, Ito K, et al. Frontal, midbrain and striatal dopamergic function in early and advanced Parkinson's disease. A 3D [(18)F]dopa-PET study. Brain 1999;122:1637-1650.
57. Williams-Gray CH, Evans JR, Goris A, et al. The distinct cognitive syndromes of Parkinson's disease: 5 year follow-up of the CamPaIGN cohort. Brain 2009;132:2958-2969.
58. Foltynie T, Goldberg TE, Lewis SJG, et al. The BDNF Val66Met polymorphism has a gender specific influence on planning ability in Parkinson's disease. J Neurol 2005;19:885-891.
59. Egan MF, Kojima M, Callicott JH, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function. Cell 2003;112:257-269.
60. Dagher A, Owen AM, Brooks DJ. The role of the striatum and hippocampus in planning: a PET activation study in Parkinson's disease. Brain 2001;124:1020-1032.
61. Williams-Gray CH, Mason SL, Evans JR, Foltynie T, Brayne C, Robbins TW, Barker RA. The CamPaIGN study of Parkinson's disease: 10-year outlook in an incident population-based cohort. J Neurol Neurosurg Psychiatry 2013;84:1258-1264.
62. Knowlton BJ, Mangels JA, Squire LR. A neostriatal habit learning system in humans. Science 1996;273:1399-1402.
63. Foerde K, Shoramy D. The role of the basal ganglia in learning and memory: insight from Parkinson's disease. Neurobiol Learn Mem 2011;96:624-636.
64. Balleine BW, O'Doherty JP. Human and rodent homologies in action control: Corticostriatal determinants of goal-directed and habitual action. Neuropsychopharmacology 2010;35:48-69.
65. de Wit S, Standing HR, Devito EE, et al. Reliance on habits at the expense of goal-directed control following dopamine precursor depletion. Psychopharmacology 2012;219:621-631.
66. Wunderlich K, Smittenaar P, Dolan R. Dopamine enhances model-free over model-based choice behavior. Neuron 2012;75:418-424.
67. Faure A, Haberland U, Conde F, et al. Lesion to the nigrostriatal dopamine system disrupts stimulus-response habit formation. J Neurosci 2005;25:2771-2780.
68. de Wit S, Barker RA, Dickinson A, et al. Habitual versus goal-directed action control in Parkinson's disease. J Cogn Neurosci 2011;23:1218-1229.
69. Czernecki V, Pillon B, Houeto JL, et al. Motivation, reward, and Parkinson's disease: influence of dopatherapy. Neuropsychologia 2002;40:2257-2267.
70. Myers CE, Shohamy D, Gluck MA, et al. Dissociating hippocampal versus basal ganglia contributions to learning and transfer. J Cogn Neurosci 2003;15:185-193.
71. Moustafa AA, Keri S, Herzallah MM, et al. A neural model of hippocampal-striatal interactions in associative learning and transfer generalization in various neurological and psychiatric patients. Brain Cogn 2010;74:132-144.
72. Moustafa AA, Gluck MA. A neurocomputational model of dopamine and prefrontal-striatal interactions during multicue category learning by Parkinson patients. J Cogn Neurosci 2011;23:151-167.
73. O'Callaghan C, Moustafa AA, de Wit S, Shine JM, Robbins TW, Lewis SJ, Hornberger M. Fronto-striatal gray matter contributions to discrimination learning in Parkinson's disease [serial online]. Front Comput Neurosci 2013;7:180.
74. Shiner T, Seymour, B, Wunderlich K. Dopamine and performance in a reinforcement learning task: evidence from Parkinson's disease. Brain 2012;135:1871-1883.
75. Shohamy D, Myers CE, Onlaor S, et al. Role of the basal ganglia in category learning: how do patients with Parkinson's disease learn? Behav Neurosci 2004;118:676-686.
76. Shohamy D, Myers CE, Geghman KD, et al. L-dopa impairs learning, but spares generalization, in Parkinson's disease. Neuropsychologia 2006;44:774-784.
77. Smittenaar P, Chase HW, Aarts E, et al. Decomposing effects of dopaminergic medication in Parkinson's disease on probabilistic action selection-learning or performance? Eur J Neurosci 2012;35:1144-1151.
78. Ell SW, Weinstein A, Ivry RB. Rule-based categorization deficits in focal basal ganglia lesion and Parkinson's disease patients. Neuropsychologia 2010;48:2974-2986.
79. Frank MJ, Seeberger LC, O'Reilly RC. By carrot or by stick: cognitive reinforcement learning in parkinsonism. Science 2004;306:1940-1943.
80. Frank MJ. Dynamic dopamine modulation in the basal ganglia: a neurocomputational account of cognitive deficits in medicated and nonmedicated parkinsonism. J Cogn Neurosci 2005;17:51-72.
81. Cools R, Altamirano L, D'Esposito M. Reversal learning in Parkinson's disease depends on medication status and outcome valence. Neuropsychologia 2006;44:1663-1673.
82. Moustafa A, Cohen MX, Sherman SJ, et al. A role for dopamine in temporal decision making and reward maximization in parkinsonism. J. Neurosci 2008;28:12294-12304.
83. Bodi N, Keri S, Nagy H, et al. Reward-learning and the novelty-seeking personality: a between-and within-subjects study of the effects of dopamine agonists on young Parkinson's patients. Brain 2009;132;2385-2395.
84. Palminteri S, Lebreton M, Worbe Y, et al. Pharmacological modulation of subliminal learning in Parkinson's and Tourette's syndromes. Proc Natl Acad Sci USA 2009;106:19179-19184.
85. Voon V, Pessiglione M, Brezing C, et al. Mechanisms underlying dopamine-mediated reward bias in compulsive behaviors. Neuron 2010;65:135-142.
86. Rutledge RB, Lazzaro SC, Lau B, et al. Dopaminergic drugs modulate learning rates and perseveration in Parkinson's patients in a dynamic foraging task. J. Neurosci 2009;29:15104-15114.
87. Berridge KC. The debate over dopamine's role in reward: the case for incentive salience. Psychopharmacology 2007;191:391-431.
88. Robbins TW, Everitt BJ. A role for mesencephalic dopamine in activation: commentary on Berridge (2006). Psychopharmacology 2007;191:433-437.
89. Dalley JW, Laane K, Theobald DEH, et al. Time-limited modulation of appetitive Pavlovian memory by D1 and NMDA receptors in the nucleus accumbens. Proc Natl Acad Sci USA 2005;102:6189-6194.
90. Lawrence AD, Goerendt IK, Brooks DJ. Apathy blunts neural response to money in Parkinson's disease. Soc Neurosci 2011;6:653-662.
91. O'Doherty JP. Contributions of the ventromedial prefrontal cortex to goal-directed action selection. Ann NY Acad Sci 2011;1239:118-129.
92. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006;30:1-23.
93. Swainson R, SenGupta D, Shetty T, et al. Impaired dimensional selection but intact use of reward feedback during visual discrimination learning in Parkinson's disease. Neuropsychologia 2006;44:1290-1304.
94. Price A, Filoteo JV, Maddox WT. Rule-based category learning in patients with Parkinson's disease. Neuropsychologia 2009;47:1213-1226.
95. Frisina PG, Haroutunian V, Libow LS. The neuropathological basis for depression in Parkinson's disease. Parkinsonism Relat Disord 2009;15:144-148.
96. Zheng Y, Altena E, Nombela-Otero C, et al. Selective serotonin reuptake inhibition modulates impulsivity in Parkinson's disease. Brain 2014, in press.
97. Weintraub D, Mavandadi S, E. Mamikonyan E, et al. Atomoxetine for depression and other neuropsychiatric symptoms in Parkinson disease. Neurology 2010;75:448-455.
98. Marsh L, Biglan K, Gerstenhaber M, et al. Atomoxetine for the treatment of executive dysfunction in Parkinson's disease: a pilot open-label study. Mov Disord 2009;24:277-282.
99. Zheng Y, Altena E, Nombela-Otero C, et al. Improving impulsivity in Parkinson's disease by atomoxetine. Biol Psychiatry 2014. In press.
100. Perry EK, Perry RH. Acetylcholine and hallucinations: disease-related compared to drug-induced alterations in human consciousness. Brain Cogn 1995;28:240-258.
101. Kehagia AA, Barker RA, Robbins TW. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in Parkinson's disease. Lancet Neurol 2010;9:1200-1213.
102. Williams-Gray CH, Foltynie T, Brayne CE, et al. Evolution of cognitive dysfunction in an incident Parkinson's disease cohort. Brain 2007;130:1787-1798.
103. Goris A, Williams-Gray CH, Clark GR, et al. Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease. Ann Neurol 2007:62:145-153.
104. Yarnall AY, Breen DP, Duncan GW, et al. Characterising mild cognitive impairment in incident Parkinson's disease: the ICICLE PD study. Neurology 2014;82:308-316.
105. Aarsland D, Zaccai J, Brayne C. A systematic review of prevalence studies of dementia in Parkinson's disease. Mov Disord 2005;20:1255-1263.
106. Foltynie T, Brayne CE, Robbins TW, et al. The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 2004;127:550-560.
107. Owen AM, Sahakian BJ, Hodges JR. et al. Dopamine-dependent fronto-striatal planning deficits in early Parkinson's disease. Neuropsychology 1995;9:126-140.
108. Baker SC, Rogers RD, Owen AM, et al. Neural systems engaged by planning: a PET study of the Tower of London task. Neuropsychologia 1996;34:515-526.
109. Owen AM, Sahakian BJ, Semple J, et al. Visuo-spatial short-term recognition memory and learning after temporal lobe excisions, frontal lobe excisions or amygdalo-hippocampectomy in man. Neuropsychologia 1995;33:1-24.
110. Lewis SJG, Foltynie T, Blackwell AD, et al. Heterogeneity of Parkinson's disease in the early clinical stages using a data driven approach. J Neurol Neurosurg Psychiatry 2005;76:343-348.
111. Williams-Gray CH, Hampshire A, Robbins TW, et al. Catechol-O-methyltransferase Val158Met genotype influences frontoparietal activity during planning in patients with Parkinson's disease. J Neurosci 2007;27:4832-4838.